{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:27:04Z","timestamp":1792898824080,"version":"4.5.0"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,10,18]],"date-time":"2017-10-18T00:00:00Z","timestamp":1508284800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s10555-017-9705-x","type":"journal-article","created":{"date-parts":[[2017,10,18]],"date-time":"2017-10-18T02:54:18Z","timestamp":1508295258000},"page":"717-736","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing"],"prefix":"10.1007","volume":"36","author":[{"given":"Claire L.","family":"Soave","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q. Ping","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,18]]},"reference":[{"issue":"1","key":"9705_CR1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0092-8674(94)90396-4","volume":"79","author":"A Ciechanover","year":"1994","unstructured":"Ciechanover, A. (1994). The ubiquitin-proteasome proteolytic pathway. Cell, 79(1), 13\u201321.","journal-title":"Cell"},{"issue":"2","key":"9705_CR2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0955-0674(95)80031-X","volume":"7","author":"M Hochstrasser","year":"1995","unstructured":"Hochstrasser, M. (1995). Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Current Opinion in Cell Biology, 7(2), 215\u2013223.","journal-title":"Current Opinion in Cell Biology"},{"issue":"3\u20134","key":"9705_CR3","first-page":"131","volume":"378","author":"AL Goldberg","year":"1997","unstructured":"Goldberg, A. L., Akopian, T. N., Kisselev, A. F., Lee, D. H., & Rohrwild, M. (1997). New insights into the mechanisms and importance of the proteasome in intracellular protein degradation. Biological Chemistry, 378(3\u20134), 131\u2013140.","journal-title":"Biological Chemistry"},{"issue":"6","key":"9705_CR4","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2174\/1568009614666140804154511","volume":"14","author":"QP Dou","year":"2014","unstructured":"Dou, Q. P., & Zonder, J. A. (2014). Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. Current Cancer Drug Targets, 14(6), 517\u2013536.","journal-title":"Current Cancer Drug Targets"},{"issue":"Pt 2","key":"9705_CR5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1242\/jcs.091199","volume":"125","author":"A Mocciaro","year":"2012","unstructured":"Mocciaro, A., & Rape, M. (2012). Emerging regulatory mechanisms in ubiquitin-dependent cell cycle control. Journal of Cell Science, 125(Pt 2), 255\u2013263. https:\/\/doi.org\/10.1242\/jcs.091199 .","journal-title":"Journal of Cell Science"},{"issue":"4","key":"9705_CR6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/sj.cdd.4400505","volume":"6","author":"RZ Orlowski","year":"1999","unstructured":"Orlowski, R. Z. (1999). The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death & Differentiation, 6(4), 303.","journal-title":"Cell Death & Differentiation"},{"issue":"4","key":"9705_CR7","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.dnarep.2009.01.017","volume":"8","author":"A Daulny","year":"2009","unstructured":"Daulny, A., & Tansey, W. P. (2009). Damage control: DNA repair, transcription, and the ubiquitin\u2013proteasome system. DNA Repair, 8(4), 444\u2013448. https:\/\/doi.org\/10.1016\/j.dnarep.2009.01.017 .","journal-title":"DNA Repair"},{"issue":"10","key":"9705_CR8","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1242\/jcs.112.10.1417","volume":"112","author":"GJ Strous","year":"1999","unstructured":"Strous, G. J., & Govers, R. (1999). The ubiquitin-proteasome system and endocytosis. Journal of Cell Science, 112(10), 1417.","journal-title":"Journal of Cell Science"},{"issue":"6","key":"9705_CR9","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/leu.2009.8","volume":"23","author":"T Ruckrich","year":"2009","unstructured":"Ruckrich, T., Kraus, M., Gogel, J., Beck, A., Ovaa, H., Verdoes, M., et al. (2009). Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia, 23(6), 1098\u20131105. https:\/\/doi.org\/10.1038\/leu.2009.8 .","journal-title":"Leukemia"},{"issue":"3","key":"9705_CR10","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1158\/1535-7163.mct-11-0555","volume":"11","author":"N Rahimi","year":"2012","unstructured":"Rahimi, N. (2012). The ubiquitin-proteasome system meets angiogenesis. Molecular Cancer Therapeutics, 11(3), 538\u2013548. https:\/\/doi.org\/10.1158\/1535-7163.mct-11-0555 .","journal-title":"Molecular Cancer Therapeutics"},{"issue":"9","key":"9705_CR11","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1128\/mcb.01737-08","volume":"29","author":"P Xie","year":"2009","unstructured":"Xie, P., Fan, Y., Zhang, H., Zhang, Y., She, M., Gu, D., et al. (2009). CHIP represses myocardin-induced smooth muscle cell differentiation via ubiquitin-mediated proteasomal degradation. Molecular and Cellular Biology, 29(9), 2398\u20132408. https:\/\/doi.org\/10.1128\/mcb.01737-08 .","journal-title":"Molecular and Cellular Biology"},{"issue":"8","key":"9705_CR12","first-page":"726","volume":"5","author":"Y Tu","year":"2012","unstructured":"Tu, Y., Chen, C., Pan, J., Xu, J., Zhou, Z.-G., & Wang, C.-Y. (2012). The ubiquitin proteasome pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis. International Journal of Clinical and Experimental Pathology, 5(8), 726\u2013738.","journal-title":"International Journal of Clinical and Experimental Pathology"},{"issue":"21","key":"9705_CR13","doi-asserted-by":"publisher","first-page":"10478","DOI":"10.1158\/0008-5472.can-06-3017","volume":"66","author":"V Milacic","year":"2006","unstructured":"Milacic, V., Chen, D., Ronconi, L., Landis-Piwowar, K. R., Fregona, D., & Dou, Q. P. (2006). A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts. Cancer Research, 66(21), 10478\u201310486. https:\/\/doi.org\/10.1158\/0008-5472.can-06-3017 .","journal-title":"Cancer Research"},{"issue":"4","key":"9705_CR14","doi-asserted-by":"publisher","first-page":"525","DOI":"10.4155\/fmc.11.187","volume":"4","author":"L Dalla Via","year":"2012","unstructured":"Dalla Via, L., Nardon, C., & Fregona, D. (2012). Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future. Future Medicinal Chemistry, 4(4), 525\u2013543. https:\/\/doi.org\/10.4155\/fmc.11.187 .","journal-title":"Future Medicinal Chemistry"},{"issue":"2","key":"9705_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1152\/physrev.00027.2001","volume":"82","author":"MH Glickman","year":"2002","unstructured":"Glickman, M. H., & Ciechanover, A. (2002). The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiological Reviews, 82(2), 373\u2013428. https:\/\/doi.org\/10.1152\/physrev.00027.2001 .","journal-title":"Physiological Reviews"},{"key":"9705_CR16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","volume":"67","author":"A Hershko","year":"1998","unstructured":"Hershko, A., & Ciechanover, A. (1998). The ubiquitin system. Annual Review of Biochemistry, 67, 425\u2013479. https:\/\/doi.org\/10.1146\/annurev.biochem.67.1.425 .","journal-title":"Annual Review of Biochemistry"},{"issue":"1","key":"9705_CR17","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1042\/BST20150209","volume":"44","author":"VK Chaugule","year":"2016","unstructured":"Chaugule, V. K., & Walden, H. (2016). Specificity and disease in the ubiquitin system. Biochemical Society Transactions, 44(1), 212\u2013227. https:\/\/doi.org\/10.1042\/BST20150209 .","journal-title":"Biochemical Society Transactions"},{"issue":"2","key":"9705_CR18","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.cell.2008.05.046","volume":"134","author":"I Lee","year":"2008","unstructured":"Lee, I., & Schindelin, H. (2008). Structural insights into E1-catalyzed ubiquitin activation and transfer to conjugating enzymes. Cell, 134(2), 268\u2013278. https:\/\/doi.org\/10.1016\/j.cell.2008.05.046 .","journal-title":"Cell"},{"key":"9705_CR19","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-3-540-69494-6_6","volume-title":"Signalling from internalized growth factor receptors","author":"S Sigismund","year":"2004","unstructured":"Sigismund, S., Polo, S., & Di Fiore, P. P. (2004). Signaling through Monoubiquitination. In I. H. Madshus (Ed.), Signalling from internalized growth factor receptors (pp. 149\u2013185). Berlin: Springer Berlin Heidelberg."},{"issue":"37","key":"9705_CR20","doi-asserted-by":"publisher","first-page":"34739","DOI":"10.1074\/jbc.C300269200","volume":"278","author":"A Wood","year":"2003","unstructured":"Wood, A., Schneider, J., Dover, J., Johnston, M., & Shilatifard, A. (2003). The Paf1 complex is essential for histone monoubiquitination by the Rad6-Bre1 complex, which signals for histone methylation by COMPASS and Dot1p. Journal of Biological Chemistry, 278(37), 34739\u201334742. https:\/\/doi.org\/10.1074\/jbc.C300269200 .","journal-title":"Journal of Biological Chemistry"},{"issue":"32","key":"9705_CR21","doi-asserted-by":"crossref","first-page":"E4639","DOI":"10.1073\/pnas.1608644113","volume":"113","author":"O Braten","year":"2016","unstructured":"Braten, O., Livneh, I., Ziv, T., Admon, A., Kehat, I., Caspi, L. H., et al. (2016). Numerous proteins with unique characteristics are degraded by the 26S proteasome following monoubiquitination. Proceedings of the National Academy of Sciences, 113(32), E4639\u2013E4647.","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"2","key":"9705_CR22","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/iub.589","volume":"64","author":"M Sadowski","year":"2012","unstructured":"Sadowski, M., Suryadinata, R., Tan, A. R., Roesley, S. N. A., & Sarcevic, B. (2012). Protein monoubiquitination and polyubiquitination generate structural diversity to control distinct biological processes. IUBMB Life, 64(2), 136\u2013142. https:\/\/doi.org\/10.1002\/iub.589 .","journal-title":"IUBMB Life"},{"key":"9705_CR23","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3389\/fnmol.2014.00072","volume":"7","author":"G Ristic","year":"2014","unstructured":"Ristic, G., Tsou, W.-L., & Todi, S. V. (2014). An optimal ubiquitin-proteasome pathway in the nervous system: the role of deubiquitinating enzymes. Frontiers in Molecular Neuroscience, 7, 72. https:\/\/doi.org\/10.3389\/fnmol.2014.00072 .","journal-title":"Frontiers in Molecular Neuroscience"},{"key":"9705_CR24","doi-asserted-by":"publisher","first-page":"e13027","DOI":"10.7554\/eLife.13027","volume":"5","author":"CM Dambacher","year":"2016","unstructured":"Dambacher, C. M., Worden, E. J., Herzik, M. A., Martin, A., & Lander, G. C. (2016). Atomic structure of the 26S proteasome lid reveals the mechanism of deubiquitinase inhibition. eLife, 5, e13027. https:\/\/doi.org\/10.7554\/eLife.13027 .","journal-title":"eLife"},{"key":"9705_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3389\/fpls.2014.00056","volume":"5","author":"E Isono","year":"2014","unstructured":"Isono, E., & Nagel, M.-K. (2014). Deubiquitylating enzymes and their emerging role in plant biology. Frontiers in Plant Science, 5, 56. https:\/\/doi.org\/10.3389\/fpls.2014.00056 .","journal-title":"Frontiers in Plant Science"},{"issue":"3","key":"9705_CR26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/156800911794519752","volume":"11","author":"D Chen","year":"2011","unstructured":"Chen, D., Frezza, M., Schmitt, S., Kanwar, J., & Dou, Q. P. (2011). Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Current Cancer Drug Targets, 11(3), 239\u2013253.","journal-title":"Current Cancer Drug Targets"},{"key":"9705_CR27","doi-asserted-by":"publisher","unstructured":"Andreas Schweitzer, A. A., Rudack, T., Beck, F., Pfeifer, G., Plitzko, J. M., Sakata, E., Schulten, K., Forster, F., & Baumeister, W. (2016). Structure of the human 26S proteasome at a resolution of 3.9\u00a0\u00c5. Proceedings of the National Academy of Sciences of the United States. https:\/\/doi.org\/10.1073\/pnas.1608050113 .","DOI":"10.1073\/pnas.1608050113"},{"issue":"3","key":"9705_CR28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.molcel.2014.09.008","volume":"56","author":"K Paraskevopoulos","year":"2014","unstructured":"Paraskevopoulos, K., Kriegenburg, F., Tatham, M. H., R\u00f6sner, H. I., Medina, B., Larsen, I. B., et al. (2014). Dss1 is a 26S proteasome ubiquitin receptor. Molecular Cell, 56(3), 453\u2013461. https:\/\/doi.org\/10.1016\/j.molcel.2014.09.008 .","journal-title":"Molecular Cell"},{"issue":"2","key":"9705_CR29","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.chembiol.2016.12.016","volume":"24","author":"ES Weyburne","year":"2017","unstructured":"Weyburne, E. S., Wilkins, O. M., Sha, Z., Williams, D. A., Pletnev, A. A., de Bruin, G., et al. (2017). Inhibition of the proteasome \u03b22 site sensitizes triple-negative breast cancer cells to \u03b25 inhibitors and suppresses Nrf1 activation. Cell Chemical Biology, 24(2), 218\u2013230. https:\/\/doi.org\/10.1016\/j.chembiol.2016.12.016 .","journal-title":"Cell Chemical Biology"},{"issue":"8","key":"9705_CR30","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/cr.2016.86","volume":"26","author":"I Livneh","year":"2016","unstructured":"Livneh, I., Cohen-Kaplan, V., Cohen-Rosenzweig, C., Avni, N., & Ciechanover, A. (2016). The life cycle of the 26S proteasome: from birth, through regulation and function, and onto its death. Cell Research, 26(8), 869\u2013885. https:\/\/doi.org\/10.1038\/cr.2016.86 .","journal-title":"Cell Research"},{"key":"9705_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/B978-0-12-397863-9.00003-1","volume":"109","author":"DA Ferrington","year":"2012","unstructured":"Ferrington, D. A., & Gregerson, D. S. (2012). Immunoproteasomes: structure, function, and antigen presentation. Progress in Molecular Biology and Translational Science, 109, 75\u2013112. https:\/\/doi.org\/10.1016\/B978-0-12-397863-9.00003-1 .","journal-title":"Progress in Molecular Biology and Translational Science"},{"issue":"5","key":"9705_CR32","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.cell.2009.05.005","volume":"137","author":"Y Saeki","year":"2009","unstructured":"Saeki, Y., Toh-e, A., Kudo, T., Kawamura, H., & Tanaka, K. (2009). Multiple proteasome-interacting proteins assist the assembly of the yeast 19S regulatory particle. Cell, 137(5), 900\u2013913. https:\/\/doi.org\/10.1016\/j.cell.2009.05.005 .","journal-title":"Cell"},{"issue":"1","key":"9705_CR33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2183\/pjab.85.12","volume":"85","author":"K Tanaka","year":"2009","unstructured":"Tanaka, K. (2009). The proteasome: overview of structure and functions. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences, 85(1), 12\u201336. https:\/\/doi.org\/10.2183\/pjab.85.12 .","journal-title":"Proceedings of the Japan Academy. Series B, Physical and Biological Sciences"},{"key":"9705_CR34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pharmthera.2014.11.002","volume":"147","author":"P D'Arcy","year":"2015","unstructured":"D'Arcy, P., Wang, X., & Linder, S. (2015). Deubiquitinase inhibition as a cancer therapeutic strategy. Pharmacology & Therapeutics, 147, 32\u201354. https:\/\/doi.org\/10.1016\/j.pharmthera.2014.11.002 .","journal-title":"Pharmacology & Therapeutics"},{"key":"9705_CR35","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1186\/2193-1801-2-566","volume":"2","author":"S Sridhar","year":"2013","unstructured":"Sridhar, S., Bhat, G., & Guruprasad, K. (2013). Analysis of bortezomib inhibitor docked within the catalytic subunits of the Plasmodium falciparum 20S proteasome. SpringerPlus, 2, 566. https:\/\/doi.org\/10.1186\/2193-1801-2-566 .","journal-title":"SpringerPlus"},{"issue":"2","key":"9705_CR36","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1081\/CNV-120030218","volume":"22","author":"J Adams","year":"2004","unstructured":"Adams, J., & Kauffman, M. (2004). Development of the proteasome inhibitor Velcade (bortezomib). Cancer Investigation, 22(2), 304\u2013311.","journal-title":"Cancer Investigation"},{"issue":"6835","key":"9705_CR37","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/35077213","volume":"411","author":"GI Evan","year":"2001","unstructured":"Evan, G. I., & Vousden, K. H. (2001). Proliferation, cell cycle and apoptosis in cancer. Nature, 411(6835), 342\u2013348. https:\/\/doi.org\/10.1038\/35077213 .","journal-title":"Nature"},{"issue":"13","key":"9705_CR38","doi-asserted-by":"publisher","first-page":"5599","DOI":"10.1158\/0008-5472.CAN-05-0201","volume":"65","author":"L Chen","year":"2005","unstructured":"Chen, L., & Madura, K. (2005). Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Research, 65(13), 5599. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-0201 .","journal-title":"Cancer Research"},{"issue":"18","key":"9705_CR39","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1073\/pnas.87.18.7071","volume":"87","author":"A Kumatori","year":"1990","unstructured":"Kumatori, A., Tanaka, K., Inamura, N., Sone, S., Ogura, T., Matsumoto, T., et al. (1990). Abnormally high expression of proteasomes in human leukemic cells. Proceedings of the National Academy of Sciences of the United States of America, 87(18), 7071\u20137075.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"45","key":"9705_CR40","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1038\/onc.2009.264","volume":"28","author":"A Arlt","year":"2009","unstructured":"Arlt, A., Bauer, I., Schafmayer, C., Tepel, J., Muerkoster, S. S., Brosch, M., et al. (2009). Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2). Oncogene, 28(45), 3983\u20133996. https:\/\/doi.org\/10.1038\/onc.2009.264 .","journal-title":"Oncogene"},{"key":"9705_CR41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0305-7372(03)00081-1","volume":"29","author":"J Adams","year":"2003","unstructured":"Adams, J. (2003). The proteasome: structure, function, and role in the cell. Cancer Treatment Reviews, 29, 3\u20139. https:\/\/doi.org\/10.1016\/S0305-7372(03)00081-1 .","journal-title":"Cancer Treatment Reviews"},{"issue":"7","key":"9705_CR42","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/bjc.1998.183","volume":"77","author":"J Delic","year":"1998","unstructured":"Delic, J., Masdehors, P., Omura, S., Cosset, J. M., Dumont, J., Binet, J. L., et al. (1998). The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. British Journal of Cancer, 77(7), 1103\u20131107.","journal-title":"British Journal of Cancer"},{"issue":"17","key":"9705_CR43","first-page":"4996","volume":"62","author":"R LeBlanc","year":"2002","unstructured":"LeBlanc, R., Catley, L. P., Hideshima, T., Lentzsch, S., Mitsiades, C. S., Mitsiades, N., et al. (2002). Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Research, 62(17), 4996\u20135000.","journal-title":"Cancer Research"},{"issue":"12","key":"9705_CR44","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/sj.cdd.4400436","volume":"5","author":"B An","year":"1998","unstructured":"An, B., Goldfarb, R. H., Siman, R., & Dou, Q. P. (1998 Dec). Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death and Differentiation, 5(12), 1062\u20137545.","journal-title":"Cell Death and Differentiation"},{"key":"9705_CR45","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.phrs.2016.01.029","volume":"105","author":"BC Lipchick","year":"2016","unstructured":"Lipchick, B. C., Fink, E. E., & Nikiforov, M. A. (2016). Oxidative stress and proteasome inhibitors in multiple myeloma. Pharmacological Research, 105, 210\u2013215. https:\/\/doi.org\/10.1016\/j.phrs.2016.01.029 .","journal-title":"Pharmacological Research"},{"issue":"151","key":"9705_CR46","doi-asserted-by":"publisher","first-page":"ra88","DOI":"10.1126\/scisignal.2001232","volume":"3","author":"X Wang","year":"2010","unstructured":"Wang, X., Yen, J., Kaiser, P., & Huang, L. (2010). Regulation of the 26S proteasome complex during oxidative stress. Science Signaling, 3(151), ra88. https:\/\/doi.org\/10.1126\/scisignal.2001232 .","journal-title":"Science Signaling"},{"issue":"5","key":"9705_CR47","doi-asserted-by":"publisher","first-page":"R110.006924","DOI":"10.1074\/mcp.M110.006924","volume":"10","author":"CT Aiken","year":"2011","unstructured":"Aiken, C. T., Kaake, R. M., Wang, X., & Huang, L. (2011). Oxidative stress-mediated regulation of proteasome complexes. Molecular & Cellular Proteomics : MCP, 10(5), R110.006924. https:\/\/doi.org\/10.1074\/mcp.M110.006924 .","journal-title":"Molecular & Cellular Proteomics : MCP"},{"issue":"12","key":"9705_CR48","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.1158\/0008-5472.CAN-06-0605","volume":"66","author":"LJA Crawford","year":"2006","unstructured":"Crawford, L. J. A., Walker, B., Ovaa, H., Chauhan, D., Anderson, K. C., Morris, T. C. M., et al. (2006). Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Research, 66(12), 6379. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-0605 .","journal-title":"Cancer Research"},{"issue":"12","key":"9705_CR49","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.4161\/cc.8.12.8798","volume":"8","author":"A Kazi","year":"2009","unstructured":"Kazi, A., Lawrence, H., Guida, W. C., McLaughlin, M. L., Springett, G. M., Berndt, N., et al. (2009). Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells. Cell Cycle, 8(12), 1940\u20131951. https:\/\/doi.org\/10.4161\/cc.8.12.8798 .","journal-title":"Cell Cycle"},{"issue":"7","key":"9705_CR50","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1158\/1535-7163.MCT-08-1169","volume":"8","author":"W-X Ding","year":"2009","unstructured":"Ding, W.-X., Ni, H.-M., Gao, W., Chen, X., Kang, J. H., Stolz, D. B., et al. (2009). Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy. Molecular Cancer Therapeutics, 8(7), 2036\u20132045. https:\/\/doi.org\/10.1158\/1535-7163.MCT-08-1169 .","journal-title":"Molecular Cancer Therapeutics"},{"issue":"6","key":"9705_CR51","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.tjog.2016.09.003","volume":"55","author":"Y Zhou","year":"2016","unstructured":"Zhou, Y., Wang, K., Zhen, S., Wang, R., & Luo, W. (2016). Carfilzomib induces G2\/M cell cycle arrest in human endometrial cancer cells via upregulation of p21Waf1\/Cip1 and p27Kip1. Taiwanese Journal of Obstetrics & Gynecology, 55(6), 847\u2013851. https:\/\/doi.org\/10.1016\/j.tjog.2016.09.003 .","journal-title":"Taiwanese Journal of Obstetrics & Gynecology"},{"key":"9705_CR52","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13046-017-0547-8","volume":"36","author":"H Huang","year":"2017","unstructured":"Huang, H., Liu, N., Liao, Y., Liu, N., Cai, J., Xia, X., et al. (2017). Platinum-containing compound platinum pyrithione suppresses ovarian tumor proliferation through proteasome inhibition. Journal of Experimental & Clinical Cancer Research : CR, 36, 79. https:\/\/doi.org\/10.1186\/s13046-017-0547-8 .","journal-title":"Journal of Experimental & Clinical Cancer Research : CR"},{"issue":"3","key":"9705_CR53","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1073\/pnas.94.3.855","volume":"94","author":"HCA Drexler","year":"1997","unstructured":"Drexler, H. C. A. (1997). Activation of the cell death program by inhibition of proteasome\u2009function. Proceedings of the National Academy of Sciences of the United States of America, 94(3), 855\u2013860.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"9705_CR54","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ajpath.2010.11.010","volume":"178","author":"B Pandit","year":"2011","unstructured":"Pandit, B., & Gartel, A. L. (2011). Proteasome inhibitors induce p53-independent apoptosis in human cancer cells. The American Journal of Pathology, 178(1), 355\u2013360. https:\/\/doi.org\/10.1016\/j.ajpath.2010.11.010 .","journal-title":"The American Journal of Pathology"},{"issue":"10","key":"9705_CR55","first-page":"1083","volume":"10","author":"S Nam","year":"2001","unstructured":"Nam, S., Smith, D. M., & Dou, Q. P. (2001). Tannic acid potently inhibits tumor cell proteasome activity, increases p27 and Bax expression, and induces G&lt;sub&gt;1&lt;\/sub&gt; arrest and apoptosis. Cancer Epidemiology Biomarkers &amp;amp; Prevention, 10(10), 1083.","journal-title":"Cancer Epidemiology Biomarkers &amp;amp; Prevention"},{"issue":"2","key":"9705_CR56","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.lungcan.2005.01.006","volume":"49","author":"MM Mortenson","year":"2005","unstructured":"Mortenson, M. M., Schlieman, M. G., Virudachalam, S., Lara, P. N., Gandara, D. G., Davies, A. M., et al. (2005). Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer. Lung Cancer, 49(2), 163\u2013170. https:\/\/doi.org\/10.1016\/j.lungcan.2005.01.006 .","journal-title":"Lung Cancer"},{"issue":"7","key":"9705_CR57","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1359-6446(03)02647-3","volume":"8","author":"J Adams","year":"2003","unstructured":"Adams, J. (2003). Potential for proteasome inhibition in the treatment of cancer. Drug Discovery Today, 8(7), 307\u2013315.","journal-title":"Drug Discovery Today"},{"issue":"12","key":"9705_CR58","doi-asserted-by":"publisher","first-page":"4829","DOI":"10.1096\/fj.15-274050","volume":"29","author":"Y Liu","year":"2015","unstructured":"Liu, Y., Huang, X., He, X., Zhou, Y., Jiang, X., Chen-Kiang, S., et al. (2015). A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function. The FASEB Journal, 29(12), 4829\u20134839. https:\/\/doi.org\/10.1096\/fj.15-274050 .","journal-title":"The FASEB Journal"},{"issue":"11","key":"9705_CR59","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/leu.2012.119","volume":"26","author":"A Lopez-Girona","year":"2012","unstructured":"Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., et al. (2012). Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia, 26(11), 2326\u20132335. https:\/\/doi.org\/10.1038\/leu.2012.119 .","journal-title":"Leukemia"},{"issue":"6","key":"9705_CR60","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/jcmm.12279","volume":"18","author":"L Kubiczkova","year":"2014","unstructured":"Kubiczkova, L., Pour, L., Sedlarikova, L., Hajek, R., & Sevcikova, S. (2014). Proteasome inhibitors\u2014molecular basis and current perspectives in multiple myeloma. Journal of Cellular and Molecular Medicine, 18(6), 947\u2013961. https:\/\/doi.org\/10.1111\/jcmm.12279 .","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"22","key":"9705_CR61","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.2174\/1381612811319220012","volume":"19","author":"D Buac","year":"2013","unstructured":"Buac, D., Shen, M., Schmitt, S., Kona, F. R., Deshmukh, R., Zhang, Z., et al. (2013). From bortezomib to other inhibitors of the proteasome and beyond. Current Pharmaceutical Design, 19(22), 4025\u20134038.","journal-title":"Current Pharmaceutical Design"},{"issue":"5","key":"9705_CR62","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","volume":"12","author":"P Moreau","year":"2011","unstructured":"Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., et al. (2011). Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. The Lancet Oncology, 12(5), 431\u2013440. https:\/\/doi.org\/10.1016\/S1470-2045(11)70081-X .","journal-title":"The Lancet Oncology"},{"key":"9705_CR63","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/2050-7771-1-13","volume":"1","author":"S L\u00fc","year":"2013","unstructured":"L\u00fc, S., & Wang, J. (2013). The resistance mechanisms of proteasome inhibitor bortezomib. Biomarker Research, 1, 13\u201313. https:\/\/doi.org\/10.1186\/2050-7771-1-13 .","journal-title":"Biomarker Research"},{"key":"9705_CR64","doi-asserted-by":"publisher","first-page":"895","DOI":"10.2147\/ott.s102756","volume":"10","author":"RE Steiner","year":"2017","unstructured":"Steiner, R. E., & Manasanch, E. E. (2017). Carfilzomib boosted combination therapy for relapsed multiple myeloma. Onco Targets Ther, 10, 895\u2013907. https:\/\/doi.org\/10.2147\/ott.s102756 .","journal-title":"Onco Targets Ther"},{"issue":"4","key":"9705_CR65","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3324\/haematol.2015.129189","volume":"101","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld, P., & Broijl, A. (2016). Treatment of relapsed and refractory multiple myeloma. Haematologica, 101(4), 396\u2013406. https:\/\/doi.org\/10.3324\/haematol.2015.129189 .","journal-title":"Haematologica"},{"issue":"17","key":"9705_CR66","doi-asserted-by":"publisher","first-page":"14814","DOI":"10.18632\/oncotarget.4530","volume":"6","author":"I Riz","year":"2015","unstructured":"Riz, I., Hawley, T. S., & Hawley, R. G. (2015). KLF4-SQSTM1\/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models. Oncotarget, 6(17), 14814\u201314831. https:\/\/doi.org\/10.18632\/oncotarget.4530 .","journal-title":"Oncotarget"},{"issue":"10","key":"9705_CR67","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1093\/jn\/130.10.2409","volume":"130","author":"CS Yang","year":"2000","unstructured":"Yang, C. S., & Landau, J. M. (2000). Effects of tea consumption on nutrition and health. The Journal of Nutrition, 130(10), 2409\u20132412.","journal-title":"The Journal of Nutrition"},{"issue":"16","key":"9705_CR68","doi-asserted-by":"publisher","first-page":"13322","DOI":"10.1074\/jbc.M004209200","volume":"276","author":"S Nam","year":"2001","unstructured":"Nam, S., Smith, D. M., & Dou, Q. P. (2001). Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. The Journal of Biological Chemistry, 276(16), 13322\u201313330. https:\/\/doi.org\/10.1074\/jbc.M004209200 .","journal-title":"The Journal of Biological Chemistry"},{"issue":"3","key":"9705_CR69","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00008571-199606000-00007","volume":"6","author":"HM Lachman","year":"1996","unstructured":"Lachman, H. M., Papolos, D. F., Saito, T., Yu, Y. M., Szumlanski, C. L., & Weinshilboum, R. M. (1996). Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics, 6(3), 243\u2013250.","journal-title":"Pharmacogenetics"},{"key":"9705_CR70","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1146\/annurev.pharmtox.39.1.19","volume":"39","author":"RM Weinshilboum","year":"1999","unstructured":"Weinshilboum, R. M., Otterness, D. M., & Szumlanski, C. L. (1999). Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annual Review of Pharmacology and Toxicology, 39, 19\u201352. https:\/\/doi.org\/10.1146\/annurev.pharmtox.39.1.19 .","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"2","key":"9705_CR71","first-page":"563","volume":"24","author":"K Landis-Piwowar","year":"2010","unstructured":"Landis-Piwowar, K., Chen, D., Chan, T. H., & Dou, Q. P. (2010). Inhibition of catechol-O-methyltransferase activity in human breast cancer cells enhances the biological effect of the green tea polyphenol (\u2212)-EGCG. Oncology Reports, 24(2), 563\u2013569.","journal-title":"Oncology Reports"},{"issue":"3","key":"9705_CR72","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.bmc.2009.12.034","volume":"18","author":"C Huo","year":"2010","unstructured":"Huo, C., Yang, H., Cindy Cui, Q., Dou, Q. P., & Chan, T. H. (2010). Proteasome inhibition in human breast cancer cells with high catechol-O-methyltransferase activity by green tea polyphenol EGCG analogs. Bioorganic & Medicinal Chemistry, 18(3), 1252. https:\/\/doi.org\/10.1016\/j.bmc.2009.12.034 .","journal-title":"Bioorganic & Medicinal Chemistry"},{"issue":"2","key":"9705_CR73","first-page":"209","volume":"26","author":"J Kanwar","year":"2010","unstructured":"Kanwar, J., Mohammad, I., Yang, H., Huo, C., Chan, T. H., & Dou, Q. P. (2010). Computational modeling of the potential interactions of the proteasome \u03b25 subunit and catechol-O-methyltransferase-resistant EGCG analogs. International Journal of Molecular Medicine, 26(2), 209\u2013215.","journal-title":"International Journal of Molecular Medicine"},{"issue":"6","key":"9705_CR74","doi-asserted-by":"crossref","first-page":"A352","DOI":"10.1289\/ehp.114-a352","volume":"114","author":"JR Barrett","year":"2006","unstructured":"Barrett, J. R. (2006). The science of soy: what do we really know? Environmental Health Perspectives, 114(6), A352\u2013A358.","journal-title":"Environmental Health Perspectives"},{"issue":"6","key":"9705_CR75","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0006-2952(03)00414-3","volume":"66","author":"A Kazi","year":"2003","unstructured":"Kazi, A., Daniel, K. G., Smith, D. M., Kumar, N. B., & Dou, Q. P. (2003). Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochemical Pharmacology, 66(6), 965\u2013976.","journal-title":"Biochemical Pharmacology"},{"issue":"4","key":"9705_CR76","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ptr.3342","volume":"25","author":"SH Shim","year":"2011","unstructured":"Shim, S. H. (2011). 20S proteasome inhibitory activity of flavonoids isolated from Spatholobus suberectus. Phytotherapy Research, 25(4), 615\u2013618. https:\/\/doi.org\/10.1002\/ptr.3342 .","journal-title":"Phytotherapy Research"},{"issue":"1","key":"9705_CR77","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3945\/an.110.000026","volume":"2","author":"S Egert","year":"2011","unstructured":"Egert, S., & Rimbach, G. (2011). Which sources of flavonoids: Complex diets or dietary supplements? Advances in Nutrition, 2(1), 8\u201314. https:\/\/doi.org\/10.3945\/an.110.000026 .","journal-title":"Advances in Nutrition"},{"issue":"10","key":"9705_CR78","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.bcp.2005.02.022","volume":"69","author":"D Chen","year":"2005","unstructured":"Chen, D., Daniel, K. G., Chen, M. S., Kuhn, D. J., Landis-Piwowar, K. R., & Dou, Q. P. (2005). Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochemical Pharmacology, 69(10), 1421\u20131432. https:\/\/doi.org\/10.1016\/j.bcp.2005.02.022 .","journal-title":"Biochemical Pharmacology"},{"issue":"6","key":"9705_CR79","doi-asserted-by":"publisher","first-page":"895","DOI":"10.3892\/mmr.2010.377","volume":"3","author":"JK Srivastava","year":"2010","unstructured":"Srivastava, J. K., Shankar, E., & Gupta, S. (2010). Chamomile: a herbal medicine of the past with bright future. Molecular Medicine Reports, 3(6), 895\u2013901. https:\/\/doi.org\/10.3892\/mmr.2010.377 .","journal-title":"Molecular Medicine Reports"},{"issue":"6","key":"9705_CR80","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/bcr1797","volume":"9","author":"D Chen","year":"2007","unstructured":"Chen, D., Landis-Piwowar, K. R., Chen, M. S., & Dou, Q. P. (2007). Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts. Breast Cancer Research, 9(6), R80.","journal-title":"Breast Cancer Research"},{"issue":"2","key":"9705_CR81","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0163-7258(00)00039-5","volume":"86","author":"R Yuan","year":"2000","unstructured":"Yuan, R., & Lin, Y. (2000). Traditional Chinese medicine. Pharmacology & Therapeutics, 86(2), 191\u2013198. https:\/\/doi.org\/10.1016\/S0163-7258(00)00039-5 .","journal-title":"Pharmacology & Therapeutics"},{"issue":"4","key":"9705_CR82","first-page":"275","volume":"176","author":"KV Ergil","year":"2002","unstructured":"Ergil, K. V., Kramer, E. J., & Ng, A. T. (2002). Chinese herbal medicines. Western Journal of Medicine, 176(4), 275\u2013279.","journal-title":"Western Journal of Medicine"},{"issue":"12","key":"9705_CR83","doi-asserted-by":"publisher","first-page":"e14153","DOI":"10.1371\/journal.pone.0014153","volume":"5","author":"Y Dai","year":"2010","unstructured":"Dai, Y., DeSano, J., Tang, W., Meng, X., Meng, Y., Burstein, E., et al. (2010). Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB. PLoS One, 5(12), e14153. https:\/\/doi.org\/10.1371\/journal.pone.0014153 .","journal-title":"PLoS One"},{"issue":"5","key":"9705_CR84","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1158\/0008-5472.CAN-09-3201","volume":"70","author":"X Pang","year":"2010","unstructured":"Pang, X., Yi, Z., Zhang, J., Lu, B., Sung, B., Qu, W., et al. (2010). Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT\/mammalian target of rapamycin pathway. Cancer Research, 70(5), 1951\u20131959. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-3201 .","journal-title":"Cancer Research"},{"issue":"2","key":"9705_CR85","doi-asserted-by":"publisher","first-page":"263","DOI":"10.4161\/cbt.11.2.13959","volume":"11","author":"SM Raja","year":"2011","unstructured":"Raja, S. M., Clubb, R. J., Ortega-Cava, C., Williams, S. H., Bailey, T. A., Duan, L., et al. (2011). Anticancer activity of celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. Cancer Biology & Therapy, 11(2), 263\u2013276. https:\/\/doi.org\/10.4161\/cbt.11.2.13959 .","journal-title":"Cancer Biology & Therapy"},{"issue":"9","key":"9705_CR86","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1158\/0008-5472.can-05-4529","volume":"66","author":"H Yang","year":"2006","unstructured":"Yang, H., Chen, D., Cui, Q. C., Yuan, X., & Dou, Q. P. (2006). Celastrol, a triterpene extracted from the Chinese \u201cThunder of God Vine,\u201d is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Research, 66(9), 4758\u20134765. https:\/\/doi.org\/10.1158\/0008-5472.can-05-4529 .","journal-title":"Cancer Research"},{"issue":"6","key":"9705_CR87","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.ccell.2017.05.003","volume":"31","author":"K Mahajan","year":"2017","unstructured":"Mahajan, K., Malla, P., Lawrence, H. R., Chen, Z., Kumar-Sinha, C., Malik, R., et al. (2017). ACK1\/TNK2 regulates histone H4 Tyr88-phosphorylation and AR gene expression in castration-resistant prostate cancer. Cancer Cell, 31(6), 790\u2013803.e798. https:\/\/doi.org\/10.1016\/j.ccell.2017.05.003 .","journal-title":"Cancer Cell"},{"issue":"12","key":"9705_CR88","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1158\/1541-7786.mcr-09-0243","volume":"7","author":"M Chen","year":"2009","unstructured":"Chen, M., Rose, A. E., Doudican, N., Osman, I., & Orlow, S. J. (2009). Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells. Molecular Cancer Research, 7(12), 1946\u20131953. https:\/\/doi.org\/10.1158\/1541-7786.mcr-09-0243 .","journal-title":"Molecular Cancer Research"},{"issue":"1","key":"9705_CR89","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/jcb.21399","volume":"103","author":"H Yang","year":"2008","unstructured":"Yang, H., Landis-Piwowar, K. R., Lu, D., Yuan, P., Li, L., Reddy, G. P., et al. (2008). Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells. Journal of Cellular Biochemistry, 103(1), 234\u2013244. https:\/\/doi.org\/10.1002\/jcb.21399 .","journal-title":"Journal of Cellular Biochemistry"},{"issue":"1","key":"9705_CR90","first-page":"1","volume":"31","author":"L Lu","year":"2011","unstructured":"Lu, L., Kanwar, J., Schmitt, S., Cui, Q. C., Zhang, C., Zhao, C., et al. (2011). Inhibition of tumor cellular proteasome activity by triptolide extracted from the Chinese medicinal plant 'thunder god vine'. Anticancer Research, 31(1), 1\u201310.","journal-title":"Anticancer Research"},{"issue":"10","key":"9705_CR91","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1002\/ijc.24195","volume":"124","author":"H Yang","year":"2009","unstructured":"Yang, H., Zhou, P., Huang, H., Chen, D., Ma, N., Cui, Q. C., et al. (2009). Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. International Journal of Cancer, 124(10), 2450\u20132459. https:\/\/doi.org\/10.1002\/ijc.24195 .","journal-title":"International Journal of Cancer"},{"issue":"7","key":"9705_CR92","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.3390\/molecules14072373","volume":"14","author":"MH Mirjalili","year":"2009","unstructured":"Mirjalili, M. H., Moyano, E., Bonfill, M., Cusido, R. M., & Palazon, J. (2009). Steroidal lactones from Withania somnifera, an ancient plant for novel medicine. Molecules, 14(7), 2373\u20132393. https:\/\/doi.org\/10.3390\/molecules14072373 .","journal-title":"Molecules"},{"issue":"2","key":"9705_CR93","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1124\/mol.106.030015","volume":"71","author":"H Yang","year":"2007","unstructured":"Yang, H., Shi, G., & Dou, Q. P. (2007). The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from \u201cIndian winter cherry\u201d. Molecular Pharmacology, 71(2), 426\u2013437. https:\/\/doi.org\/10.1124\/mol.106.030015 .","journal-title":"Molecular Pharmacology"},{"issue":"11","key":"9705_CR94","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1007\/s00018-008-7452-4","volume":"65","author":"H Hatcher","year":"2008","unstructured":"Hatcher, H., Planalp, R., Cho, J., Torti, F. M., & Torti, S. V. (2008). Curcumin: From ancient medicine to current clinical trials. Cellular and molecular life sciences : CMLS, 65(11), 1631\u20131652. https:\/\/doi.org\/10.1007\/s00018-008-7452-4 .","journal-title":"Cellular and molecular life sciences : CMLS"},{"issue":"18","key":"9705_CR95","doi-asserted-by":"publisher","first-page":"7283","DOI":"10.1158\/0008-5472.CAN-07-6246","volume":"68","author":"V Milacic","year":"2008","unstructured":"Milacic, V., Banerjee, S., Landis-Piwowar, K. R., Sarkar, F. H., Majumdar, A. P. N., & Dou, Q. P. (2008). Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Research, 68(18), 7283\u20137292. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-6246 .","journal-title":"Cancer Research"},{"issue":"4","key":"9705_CR96","first-page":"447","volume":"26","author":"SB Wan","year":"2010","unstructured":"Wan, S. B., Yang, H., Zhou, Z., Cui, Q. C., Chen, D., Kanwar, J., et al. (2010). Evaluation of curcumin acetates and amino acid conjugates as proteasome inhibitors. International Journal of Molecular Medicine, 26(4), 447\u2013455.","journal-title":"International Journal of Molecular Medicine"},{"key":"9705_CR97","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bcp.2017.04.032","volume":"137","author":"X Yue","year":"2017","unstructured":"Yue, X., Zuo, Y., Ke, H., Luo, J., Lou, L., Qin, W., et al. (2017). Identification of 4-arylidene curcumin analogues as novel proteasome inhibitors for potential anticancer agents targeting 19S regulatory particle associated deubiquitinase. Biochemical Pharmacology, 137, 29\u201350. https:\/\/doi.org\/10.1016\/j.bcp.2017.04.032 .","journal-title":"Biochemical Pharmacology"},{"issue":"6442","key":"9705_CR98","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/365182a0","volume":"365","author":"T Henkel","year":"1993","unstructured":"Henkel, T., Machleidt, T., Alkalay, I., Kronke, M., Ben-Neriah, Y., & Baeuerle, P. A. (1993). Rapid proteolysis of I[kappa]B-[alpha] is necessary for activation of transcription factor NF-[kappa]B. Nature, 365(6442), 182\u2013185. https:\/\/doi.org\/10.1038\/365182a0 .","journal-title":"Nature"},{"key":"9705_CR99","doi-asserted-by":"publisher","unstructured":"Kashyap, D., Mondal, R., Tuli, H. S., Kumar, G., & Sharma, A. K. (2016). Molecular targets of gambogic acid in cancer: recent trends and advancements. Tumor Biology, 37(10), 12915\u201312925. https:\/\/doi.org\/10.1007\/s13277-016-5194-8.","DOI":"10.1007\/s13277-016-5194-8."},{"issue":"1","key":"9705_CR100","first-page":"679","volume":"16","author":"ZT Zhou","year":"2007","unstructured":"Zhou, Z. T., & W. J. (2007). Phase I human tolerability trial of gambogic acid. Chin J New Drugs, 16(1), 679\u2013682.","journal-title":"Chin J New Drugs"},{"issue":"1","key":"9705_CR101","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.celrep.2012.11.023","volume":"3","author":"X Li","year":"2013","unstructured":"Li, X., Liu, S., Huang, H., Liu, N., Zhao, C., Liao, S., et al. (2013). Gambogic acid is a tissue-specific proteasome inhibitor in vitro and in vivo. Cell Reports, 3(1), 211\u2013222. https:\/\/doi.org\/10.1016\/j.celrep.2012.11.023 .","journal-title":"Cell Reports"},{"issue":"1","key":"9705_CR102","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1158\/1078-0432.ccr-13-1063","volume":"20","author":"X Shi","year":"2014","unstructured":"Shi, X., Chen, X., Li, X., Lan, X., Zhao, C., Liu, S., et al. (2014). Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation. Clinical Cancer Research, 20(1), 151\u2013163. https:\/\/doi.org\/10.1158\/1078-0432.ccr-13-1063 .","journal-title":"Clinical Cancer Research"},{"key":"9705_CR103","doi-asserted-by":"publisher","first-page":"9694","DOI":"10.1038\/srep09694","volume":"5","author":"X Shi","year":"2015","unstructured":"Shi, X., Lan, X., Chen, X., Zhao, C., Li, X., Liu, S., et al. (2015). Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition. Scientific Reports, 5, 9694. https:\/\/doi.org\/10.1038\/srep09694 .","journal-title":"Scientific Reports"},{"issue":"45","key":"9705_CR104","doi-asserted-by":"publisher","first-page":"5106","DOI":"10.1039\/C3CC41143E","volume":"49","author":"NPE Barry","year":"2013","unstructured":"Barry, N. P. E., & Sadler, P. J. (2013). Exploration of the medical periodic table: towards new targets. Chemical Communications, 49(45), 5106\u20135131. https:\/\/doi.org\/10.1039\/C3CC41143E .","journal-title":"Chemical Communications"},{"issue":"6","key":"9705_CR105","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s00280-016-2976-z","volume":"77","author":"S Dilruba","year":"2016","unstructured":"Dilruba, S., & Kalayda, G. V. (2016). Platinum-based drugs: past, present and future. Cancer Chemotherapy and Pharmacology, 77(6), 1103\u20131124. https:\/\/doi.org\/10.1007\/s00280-016-2976-z .","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"3","key":"9705_CR106","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s10787-007-0018-5","volume":"16","author":"ERT Tiekink","year":"2008","unstructured":"Tiekink, E. R. T. (2008). Anti-cancer potential of gold complexes. Inflammopharmacology, 16(3), 138\u2013142. https:\/\/doi.org\/10.1007\/s10787-007-0018-5 .","journal-title":"Inflammopharmacology"},{"issue":"1","key":"9705_CR107","doi-asserted-by":"publisher","first-page":"e84248","DOI":"10.1371\/journal.pone.0084248","volume":"9","author":"C Nardon","year":"2014","unstructured":"Nardon, C., Schmitt, S. M., Yang, H., Zuo, J., Fregona, D., & Dou, Q. P. (2014). Gold(III)-dithiocarbamato Peptidomimetics in the forefront of the targeted anticancer therapy: preclinical studies against human breast neoplasia. PLoS One, 9(1), e84248. https:\/\/doi.org\/10.1371\/journal.pone.0084248 .","journal-title":"PLoS One"},{"issue":"9","key":"9705_CR108","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1158\/0008-5472.can-13-2033","volume":"74","author":"W Fiskus","year":"2014","unstructured":"Fiskus, W., Saba, N., Shen, M., Ghias, M., Liu, J., Gupta, S. D., et al. (2014). Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer Research, 74(9), 2520\u20132532. https:\/\/doi.org\/10.1158\/0008-5472.can-13-2033 .","journal-title":"Cancer Research"},{"key":"9705_CR109","unstructured":"Phase I and II study of auranofin in chronic lymphocytic leukemia (CLL). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01419691"},{"issue":"6","key":"9705_CR110","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10787-012-0149-1","volume":"20","author":"JM Madeira","year":"2012","unstructured":"Madeira, J. M., Gibson, D. L., Kean, W. F., & Klegeris, A. (2012). The biological activity of auranofin: implications for novel treatment of diseases. Inflammopharmacology, 20(6), 297\u2013306. https:\/\/doi.org\/10.1007\/s10787-012-0149-1 .","journal-title":"Inflammopharmacology"},{"issue":"14","key":"9705_CR111","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.18632\/oncotarget.2113","volume":"5","author":"N Liu","year":"2014","unstructured":"Liu, N., Li, X., Huang, H., Zhao, C., Liao, S., Yang, C., et al. (2014). Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. Oncotarget, 5(14), 5453\u20135471. 10.18632\/oncotarget.2113 .","journal-title":"Oncotarget"},{"issue":"19","key":"9705_CR112","doi-asserted-by":"publisher","first-page":"9118","DOI":"10.18632\/oncotarget.2361","volume":"5","author":"X Chen","year":"2014","unstructured":"Chen, X., Shi, X., Zhao, C., Li, X., Lan, X., Liu, S., et al. (2014). Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr\/Abl-dependent and -independent mechanisms. Oncotarget, 5(19), 9118\u20139132. 10.18632\/oncotarget.2361 .","journal-title":"Oncotarget"},{"issue":"3","key":"9705_CR113","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10565-010-9178-y","volume":"27","author":"A Varela-Ramirez","year":"2011","unstructured":"Varela-Ramirez, A., Costanzo, M., Carrasco, Y. P., Pannell, K. H., & Aguilera, R. J. (2011). Cytotoxic effects of two organotin compounds and their mode of inflicting cell death on four mammalian cancer cells. Cell Biology and Toxicology, 27(3), 159\u2013168. https:\/\/doi.org\/10.1007\/s10565-010-9178-y .","journal-title":"Cell Biology and Toxicology"},{"issue":"1","key":"9705_CR114","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0010-8545(01)00399-X","volume":"224","author":"L Pellerito","year":"2002","unstructured":"Pellerito, L., & Nagy, L. (2002). Organotin(IV)n+ complexes formed with biologically active ligands: equilibrium and structural studies, and some biological aspects. Coordination Chemistry Reviews, 224(1), 111\u2013150. https:\/\/doi.org\/10.1016\/S0010-8545(01)00399-X .","journal-title":"Coordination Chemistry Reviews"},{"issue":"1","key":"9705_CR115","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/(SICI)1099-0739(199901)13:1<29::AID-AOC809>3.0.CO;2-D","volume":"13","author":"M Nath","year":"1999","unstructured":"Nath, M., Yadav, R., Eng, G., & Musingarimi, P. (1999). Characteristic spectral studies and in vitro antimicrobial and in vivo multi-infection antifungal activities in mice of new organotin(IV) derivatives of heterocyclic amino acids. Applied Organometallic Chemistry, 13(1), 29\u201337. https:\/\/doi.org\/10.1002\/(SICI)1099-0739(199901)13:1<29::AID-AOC809>3.0.CO;2-D .","journal-title":"Applied Organometallic Chemistry"},{"issue":"3","key":"9705_CR116","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1289\/ehp.11865","volume":"117","author":"G Shi","year":"2009","unstructured":"Shi, G., Chen, D., Zhai, G., Chen, M. S., Cui, Q. C., Zhou, Q., et al. (2009). The proteasome is a molecular target of environmental toxic organotins. Environmental Health Perspectives, 117(3), 379\u2013386. https:\/\/doi.org\/10.1289\/ehp.11865 .","journal-title":"Environmental Health Perspectives"},{"issue":"1","key":"9705_CR117","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ctrv.2008.07.004","volume":"35","author":"A Gupte","year":"2009","unstructured":"Gupte, A., & Mumper, R. J. (2009). Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treatment Reviews, 35(1), 32\u201346. https:\/\/doi.org\/10.1016\/j.ctrv.2008.07.004 .","journal-title":"Cancer Treatment Reviews"},{"issue":"1","key":"9705_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1385\/bter:89:1:1","volume":"89","author":"HW Kuo","year":"2002","unstructured":"Kuo, H. W., Chen, S. F., Wu, C. C., Chen, D. R., & Lee, J. H. (2002). Serum and tissue trace elements in patients with breast cancer in Taiwan. Biological Trace Element Research, 89(1), 1\u201311. https:\/\/doi.org\/10.1385\/bter:89:1:1 .","journal-title":"Biological Trace Element Research"},{"issue":"1\u20133","key":"9705_CR119","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1385\/bter:114:1:41","volume":"114","author":"XL Zuo","year":"2006","unstructured":"Zuo, X. L., Chen, J. M., Zhou, X., Li, X. Z., & Mei, G. Y. (2006). Levels of selenium, zinc, copper, and antioxidant enzyme activity in patients with leukemia. Biological Trace Element Research, 114(1\u20133), 41\u201353. https:\/\/doi.org\/10.1385\/bter:114:1:41 .","journal-title":"Biological Trace Element Research"},{"issue":"5","key":"9705_CR120","first-page":"1121","volume":"137","author":"SS Brem","year":"1990","unstructured":"Brem, S. S., Zagzag, D., Tsanaclis, A. M., Gately, S., Elkouby, M. P., & Brien, S. E. (1990). Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. The American Journal of Pathology, 137(5), 1121\u20131142.","journal-title":"The American Journal of Pathology"},{"issue":"6","key":"9705_CR121","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.bcp.2003.10.031","volume":"67","author":"KG Daniel","year":"2004","unstructured":"Daniel, K. G., Gupta, P., Harbach, R. H., Guida, W. C., & Dou, Q. P. (2004). Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. Biochemical Pharmacology, 67(6), 1139\u20131151. https:\/\/doi.org\/10.1016\/j.bcp.2003.10.031 .","journal-title":"Biochemical Pharmacology"},{"key":"9705_CR122","doi-asserted-by":"publisher","first-page":"5240","DOI":"10.1038\/srep05240","volume":"4","author":"N Liu","year":"2014","unstructured":"Liu, N., Liu, C., Li, X., Liao, S., Song, W., Yang, C., et al. (2014). A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases. Scientific Reports, 4, 5240. https:\/\/doi.org\/10.1038\/srep05240 .","journal-title":"Scientific Reports"},{"issue":"11","key":"9705_CR123","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1016\/j.ejmech.2009.05.019","volume":"44","author":"SS Hindo","year":"2009","unstructured":"Hindo, S. S., Frezza, M., Tomco, D., Heeg, M. J., Hryhorczuk, L., McGarvey, B. R., et al. (2009). Metals in anticancer therapy: copper(II) complexes as inhibitors of the 20S proteasome. European Journal of Medicinal Chemistry, 44(11), 4353\u20134361. https:\/\/doi.org\/10.1016\/j.ejmech.2009.05.019 .","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"13","key":"9705_CR124","doi-asserted-by":"publisher","first-page":"5928","DOI":"10.1021\/ic900276g","volume":"48","author":"M Frezza","year":"2009","unstructured":"Frezza, M., Hindo, S. S., Tomco, D., Allard, M., Cui, Q. C., Heeg, M. J., et al. (2009). Comparative activities of nickel(II) and zinc(II) complexes of asymmetric [NN\u2032O] ligands as 26S proteasome inhibitors. Inorganic Chemistry, 48(13), 5928\u20135937. https:\/\/doi.org\/10.1021\/ic900276g .","journal-title":"Inorganic Chemistry"},{"issue":"1","key":"9705_CR125","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jinorgbio.2011.09.003","volume":"106","author":"CN Verani","year":"2012","unstructured":"Verani, C. N. (2012). Metal complexes as inhibitors of the 26S proteasome in tumor cells. Journal of Inorganic Biochemistry, 106(1), 59\u201367. https:\/\/doi.org\/10.1016\/j.jinorgbio.2011.09.003 .","journal-title":"Journal of Inorganic Biochemistry"},{"key":"9705_CR126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jinorgbio.2013.02.004","volume":"0","author":"Z Zhang","year":"2013","unstructured":"Zhang, Z., Bi, C., Buac, D., Fan, Y., Zhang, X., Zuo, J., et al. (2013). Organic cadmium complexes as proteasome inhibitors and apoptosis inducers in human breast cancer cells. Journal of Inorganic Biochemistry, 0, 1\u201310. https:\/\/doi.org\/10.1016\/j.jinorgbio.2013.02.004 .","journal-title":"Journal of Inorganic Biochemistry"},{"issue":"8","key":"9705_CR127","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrc2167","volume":"7","author":"L Kelland","year":"2007","unstructured":"Kelland, L. (2007). The resurgence of platinum-based cancer chemotherapy. Nature Reviews. Cancer, 7(8), 573\u2013584. https:\/\/doi.org\/10.1038\/nrc2167 .","journal-title":"Nature Reviews. Cancer"},{"issue":"11","key":"9705_CR128","first-page":"5390","volume":"44","author":"SL Rizk","year":"1984","unstructured":"Rizk, S. L., & Sky-Peck, H. H. (1984). Comparison between concentrations of trace elements in normal and neoplastic human breast tissue. Cancer Research, 44(11), 5390\u20135394.","journal-title":"Cancer Research"},{"issue":"2","key":"9705_CR129","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0009-9120(98)00096-4","volume":"32","author":"YL Huang","year":"1999","unstructured":"Huang, Y. L., Sheu, J. Y., & Lin, T. H. (1999). Association between oxidative stress and changes of trace elements in patients with breast cancer. Clinical Biochemistry, 32(2), 131\u2013136.","journal-title":"Clinical Biochemistry"},{"issue":"3","key":"9705_CR130","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0009-8981(80)90390-3","volume":"104","author":"FK Habib","year":"1980","unstructured":"Habib, F. K., Dembinski, T. C., & Stitch, S. R. (1980). The zinc and copper content of blood leucocytes and plasma from patients with benign and malignant prostates. Clinica Chimica Acta, 104(3), 329\u2013335.","journal-title":"Clinica Chimica Acta"},{"issue":"1","key":"9705_CR131","first-page":"108","volume":"47","author":"SB Nayak","year":"2003","unstructured":"Nayak, S. B., Bhat, V. R., Upadhyay, D., & Udupa, S. L. (2003). Copper and ceruloplasmin status in serum of prostate and colon cancer patients. Indian Journal of Physiology and Pharmacology, 47(1), 108\u2013110.","journal-title":"Indian Journal of Physiology and Pharmacology"},{"issue":"4","key":"9705_CR132","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000226722","volume":"46","author":"M Diez","year":"1989","unstructured":"Diez, M., Arroyo, M., Cerdan, F. J., Munoz, M., Martin, M. A., & Balibrea, J. L. (1989). Serum and tissue trace metal levels in lung cancer. Oncology, 46(4), 230\u2013234.","journal-title":"Oncology"},{"issue":"4","key":"9705_CR133","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF01731643","volume":"62","author":"L Turecky","year":"1984","unstructured":"Turecky, L., Kalina, P., Uhlikova, E., Namerova, S., & Krizko, J. (1984). Serum ceruloplasmin and copper levels in patients with primary brain tumors. Klinische Wochenschrift, 62(4), 187\u2013189.","journal-title":"Klinische Wochenschrift"},{"issue":"6","key":"9705_CR134","doi-asserted-by":"publisher","first-page":"R897","DOI":"10.1186\/bcr1322","volume":"7","author":"KG Daniel","year":"2005","unstructured":"Daniel, K. G., Chen, D., Orlu, S., Cui, Q. C., Miller, F. R., & Dou, Q. P. (2005). Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Research, 7(6), R897\u2013R908. https:\/\/doi.org\/10.1186\/bcr1322 .","journal-title":"Breast Cancer Research"},{"issue":"2","key":"9705_CR135","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00775-009-0594-5","volume":"15","author":"S Zhai","year":"2010","unstructured":"Zhai, S., Yang, L., Cui, Q. C., Sun, Y., Dou, Q. P., & Yan, B. (2010). Tumor cellular proteasome inhibition and growth suppression by 8-hydroxyquinoline and clioquinol requires their capabilities to bind copper and transport copper into cells. Journal of Biological Inorganic Chemistry, 15(2), 259\u2013269. https:\/\/doi.org\/10.1007\/s00775-009-0594-5 .","journal-title":"Journal of Biological Inorganic Chemistry"},{"issue":"1","key":"9705_CR136","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4103\/0973-1229.58820","volume":"8","author":"A Sousa De","year":"2010","unstructured":"De Sousa, A. (2010). The pharmacotherapy of alcohol dependence: a state of the art review. Mens Sana Monographs, 8(1), 69\u201382. https:\/\/doi.org\/10.4103\/0973-1229.58820 .","journal-title":"Mens Sana Monographs"},{"issue":"21","key":"9705_CR137","doi-asserted-by":"publisher","first-page":"10425","DOI":"10.1158\/0008-5472.can-06-2126","volume":"66","author":"D Chen","year":"2006","unstructured":"Chen, D., Cui, Q. C., Yang, H., & Dou, Q. P. (2006). Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Research, 66(21), 10425\u201310433. https:\/\/doi.org\/10.1158\/0008-5472.can-06-2126 .","journal-title":"Cancer Research"},{"issue":"5","key":"9705_CR138","first-page":"809","volume":"19","author":"H Pang","year":"2007","unstructured":"Pang, H., Chen, D., Cui, Q. C., & Dou, Q. P. (2007). Sodium diethyldithiocarbamate, an AIDS progression inhibitor and a copper-binding compound, has proteasome-inhibitory and apoptosis-inducing activities in cancer cells. International Journal of Molecular Medicine, 19(5), 809\u2013816.","journal-title":"International Journal of Molecular Medicine"},{"issue":"1","key":"9705_CR139","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.taap.2008.03.009","volume":"231","author":"V Milacic","year":"2008","unstructured":"Milacic, V., Chen, D., Giovagnini, L., Diez, A., Fregona, D., & Dou, Q. P. (2008). Pyrrolidine dithiocarbamate-zinc(II) and -copper(II) complexes induce apoptosis in tumor cells by inhibiting the proteasomal activity. Toxicology and Applied Pharmacology, 231(1), 24\u201333. https:\/\/doi.org\/10.1016\/j.taap.2008.03.009 .","journal-title":"Toxicology and Applied Pharmacology"},{"issue":"20","key":"9705_CR140","doi-asserted-by":"publisher","first-page":"6256","DOI":"10.1021\/jm8007807","volume":"51","author":"B Cvek","year":"2008","unstructured":"Cvek, B., Milacic, V., Taraba, J., & Dou, Q. P. (2008). Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells. Journal of Medicinal Chemistry, 51(20), 6256\u20136258. https:\/\/doi.org\/10.1021\/jm8007807 .","journal-title":"Journal of Medicinal Chemistry"},{"issue":"2","key":"9705_CR141","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/open.201402091","volume":"4","author":"C Nardon","year":"2015","unstructured":"Nardon, C., Chiara, F., Brustolin, L., Gambalunga, A., Ciscato, F., Rasola, A., et al. (2015). Gold(III)\u2013pyrrolidinedithiocarbamato derivatives as antineoplastic agents. ChemistryOpen, 4(2), 183\u2013191. https:\/\/doi.org\/10.1002\/open.201402091 .","journal-title":"ChemistryOpen"},{"key":"9705_CR142","doi-asserted-by":"publisher","first-page":"5240","DOI":"10.1038\/srep05240","volume":"4","author":"N Liu","year":"2014","unstructured":"Liu, N., Liu, C., Li, X., Liao, S., Song, W., Yang, C., et al. (2014). A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases. Scientific Reports, 4, 5240. https:\/\/doi.org\/10.1038\/srep05240 .","journal-title":"Scientific Reports"},{"issue":"45","key":"9705_CR143","doi-asserted-by":"publisher","first-page":"5916","DOI":"10.1038\/onc.2016.114","volume":"35","author":"C Zhao","year":"2016","unstructured":"Zhao, C., Chen, X., Zang, D., Lan, X., Liao, S., Yang, C., et al. (2016). A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy. Oncogene, 35(45), 5916\u20135927. https:\/\/doi.org\/10.1038\/onc.2016.114 .","journal-title":"Oncogene"},{"issue":"8","key":"9705_CR144","doi-asserted-by":"publisher","first-page":"13942","DOI":"10.18632\/oncotarget.14572","volume":"8","author":"C Zhao","year":"2017","unstructured":"Zhao, C., Chen, X., Yang, C., Zang, D., Lan, X., Liao, S., et al. (2017). Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases. Oncotarget, 8(8), 13942\u201313956. 10.18632\/oncotarget.14572 .","journal-title":"Oncotarget"},{"key":"9705_CR145","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bcp.2016.06.019","volume":"116","author":"C Zhao","year":"2016","unstructured":"Zhao, C., Chen, X., Zang, D., Lan, X., Liao, S., Yang, C., et al. (2016). Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy. Biochemical Pharmacology, 116, 22\u201338. https:\/\/doi.org\/10.1016\/j.bcp.2016.06.019 .","journal-title":"Biochemical Pharmacology"},{"key":"9705_CR146","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejmech.2017.06.013","volume":"138","author":"MF Tomasello","year":"2017","unstructured":"Tomasello, M. F., Nardon, C., Lanza, V., Di Natale, G., Pettenuzzo, N., Salmaso, S., et al. (2017). New comprehensive studies of a gold(III) dithiocarbamate complex with proven anticancer properties: aqueous dissolution with cyclodextrins, pharmacokinetics and upstream inhibition of the ubiquitin-proteasome pathway. European Journal of Medicinal Chemistry, 138, 115\u2013127. https:\/\/doi.org\/10.1016\/j.ejmech.2017.06.013 .","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"9","key":"9705_CR147","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1039\/c5sc01351h","volume":"6","author":"H An","year":"2015","unstructured":"An, H., & Statsyuk, A. V. (2015). An inhibitor of ubiquitin conjugation and aggresome formation. Chemical Science, 6(9), 5235\u20135245. https:\/\/doi.org\/10.1039\/c5sc01351h .","journal-title":"Chemical Science"},{"issue":"19","key":"9705_CR148","doi-asserted-by":"publisher","first-page":"9472","DOI":"10.1158\/0008-5472.can-07-0568","volume":"67","author":"Y Yang","year":"2007","unstructured":"Yang, Y., Kitagaki, J., Dai, R. M., Tsai, Y. C., Lorick, K. L., Ludwig, R. L., et al. (2007). Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Research, 67(19), 9472\u20139481. https:\/\/doi.org\/10.1158\/0008-5472.can-07-0568 .","journal-title":"Cancer Research"},{"issue":"11","key":"9705_CR149","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1182\/blood-2009-07-231191","volume":"115","author":"GW Xu","year":"2010","unstructured":"Xu, G. W., Ali, M., Wood, T. E., Wong, D., Maclean, N., Wang, X., et al. (2010). The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood, 115(11), 2251\u20132259. https:\/\/doi.org\/10.1182\/blood-2009-07-231191 .","journal-title":"Blood"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10555-017-9705-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-017-9705-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-017-9705-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T20:22:49Z","timestamp":1659644569000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10555-017-9705-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,18]]},"references-count":149,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["9705"],"URL":"https:\/\/doi.org\/10.1007\/s10555-017-9705-x","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,18]]}}}